search
Colorectal cancer represents 10% of all cancer diagnoses and cancer deaths around the World and is the second most common cancer in women and the third most common in men.
Of all patients diagnosed with CRC, 30% have rectal cancer and 70% have colon cancer.
Rectal cancer management is currently well established, from staging to surgical treatment, with high quality evidence supporting neoadjuvant treatment strategies.
The same is not true of colon cancer. Not only does its staging lack specificity and sensitivity, but also treatment strategies rely almost exclusively on surgical interventions.
Recently, the results of a RCT – the FOxTROT Trial favored the use of neoadjuvant chemotherapy in patients with high-risk colon cancer, but the evidence was not strong enough to define clear treatment strategies.
Improvement of imaging staging exams, longer follow-ups and new trials may help define the role of Neoadjuvant Chemotherapy in Colon cancer patients.